SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

SEGALA, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.381
AS - Asia 6.779
EU - Europa 4.755
SA - Sud America 1.091
Continente sconosciuto - Info sul continente non disponibili 424
AF - Africa 181
OC - Oceania 22
Totale 23.633
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.975
SG - Singapore 2.622
IT - Italia 1.790
CN - Cina 1.375
BR - Brasile 849
VN - Vietnam 788
PL - Polonia 777
HK - Hong Kong 578
DE - Germania 571
BD - Bangladesh 445
GB - Regno Unito 289
FI - Finlandia 285
FR - Francia 251
JP - Giappone 199
CA - Canada 193
IN - India 190
RU - Federazione Russa 164
ID - Indonesia 151
UA - Ucraina 141
SE - Svezia 129
MX - Messico 126
TR - Turchia 111
NL - Olanda 100
AR - Argentina 99
IQ - Iraq 59
AT - Austria 52
ZA - Sudafrica 51
ES - Italia 50
CO - Colombia 34
PK - Pakistan 33
EC - Ecuador 30
LT - Lituania 30
MA - Marocco 28
BE - Belgio 27
PH - Filippine 27
SA - Arabia Saudita 24
CL - Cile 23
VE - Venezuela 23
KE - Kenya 21
MY - Malesia 21
UZ - Uzbekistan 21
CR - Costa Rica 19
TN - Tunisia 19
AE - Emirati Arabi Uniti 17
AU - Australia 17
CZ - Repubblica Ceca 16
PE - Perù 15
EG - Egitto 14
IE - Irlanda 14
TH - Thailandia 14
JM - Giamaica 13
JO - Giordania 12
PY - Paraguay 12
CH - Svizzera 11
NP - Nepal 10
CM - Camerun 9
ET - Etiopia 9
HN - Honduras 9
KR - Corea 9
PS - Palestinian Territory 9
AL - Albania 8
AZ - Azerbaigian 8
BG - Bulgaria 8
DZ - Algeria 8
OM - Oman 8
DO - Repubblica Dominicana 7
IL - Israele 7
NI - Nicaragua 7
GT - Guatemala 6
PA - Panama 6
RS - Serbia 6
BH - Bahrain 5
EU - Europa 5
KZ - Kazakistan 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
BY - Bielorussia 4
DK - Danimarca 4
GE - Georgia 4
IR - Iran 4
NO - Norvegia 4
SN - Senegal 4
GR - Grecia 3
HU - Ungheria 3
LB - Libano 3
LV - Lettonia 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AO - Angola 2
BS - Bahamas 2
CY - Cipro 2
GA - Gabon 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
RO - Romania 2
SR - Suriname 2
Totale 23.171
Salva come PNG Salva come JPEG
Città #
Ashburn 1.595
Singapore 1.521
San Jose 977
Warsaw 765
Santa Clara 657
Beijing 644
Fairfield 588
Hong Kong 566
Council Bluffs 447
Chandler 348
Woodbridge 310
Ho Chi Minh City 277
Houston 257
Los Angeles 250
Munich 249
Wilmington 239
Seattle 237
New York 230
Tokyo 196
Helsinki 181
Cambridge 176
Dallas 172
Hanoi 166
Princeton 154
Lauterbourg 149
Milan 143
Ferrara 142
Jakarta 117
Ann Arbor 111
Jacksonville 107
Rome 95
London 79
Mexico City 79
São Paulo 78
Shanghai 76
Bologna 75
San Diego 73
Dong Ket 69
Orem 67
Toronto 65
Turku 64
Chicago 61
Frankfurt am Main 61
Bremen 59
Nuremberg 59
Brooklyn 55
Boardman 52
Buffalo 52
Izmir 48
Washington 48
The Dalles 46
Atlanta 45
Chennai 45
Montreal 42
Verona 41
Phoenix 40
Denver 39
Naples 39
Nanjing 38
Falls Church 37
Da Nang 36
Stockholm 36
Boston 33
Redwood City 31
Rio de Janeiro 31
San Francisco 31
Amsterdam 30
Johannesburg 30
Baghdad 28
Falkenstein 28
Dearborn 27
Addison 26
Manchester 26
Poplar 26
Moscow 25
Brussels 24
Haiphong 24
Charlotte 23
Santa Maria Di Sala 22
Belo Horizonte 21
Hefei 20
Lappeenranta 20
Tianjin 20
Vienna 20
Mumbai 18
Nairobi 18
Turin 18
Dhaka 17
San José 17
Florence 16
Palermo 16
Brasília 15
Delhi 15
Hải Dương 15
Kuala Lumpur 15
Mountain View 15
Norwalk 15
San Mateo 15
Tashkent 15
Ankara 14
Totale 14.590
Salva come PNG Salva come JPEG
Nome #
Endocardite da Bartonella henselae? Riscontro di anticorpi anti-fosfolipidi, anti-beta2-glicoproteina e anti-cardiolipina. 733
Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program 354
INTERVENTO DI FORMAZIONE/INFORMAZIONE CIRCA LE MODALITÀ DI TRASMISSIONE/PREVENZIONE DI MALATTIE SESSUALMENTE TRASMISSIBILI (SDTS) AD UNA POPOLAZIONE DI MIGRANTI RICHIEDENTI ASILO/RIFUGIATI CON OFFERTA ATTIVA DEL TEST HIV. STUDIO PILOTA NELLA PROVINCIA DI FERRARA. DATI PRELIMINARI 282
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 258
INDAGINE RETROSPETTIVA DELLE LINFOADENOPATIE INFETTIVE. RUOLO DEI TESTS MOLECOLARI. 253
Investigation of Chlamydia pneumonite and Mycoplasma spp. In clinical specimens from patients with arhritis 252
INFEZIONI DEL SISTEMA NERVOSO CENTRALE E CHLAMYDIA PNEUMONIAE. RUOLO ETIOPATOGENETICO NELLA SCLEROSI MULTIPLA 225
Factors that influence HCV related liver disease severity in Italian patients in care: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti ViRali) HCV cohort study". 217
Proportion of PLWH not vaccinated for COVID-19 in Italy and predictors 214
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 210
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 207
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 205
EPATITE CRONICA C E SINDROME DI EHLERS DANLOS (EDS). 200
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 200
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 199
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 199
The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS 195
Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area. 193
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study 191
Expression of toxoplasmic 65 kDa cystic mRNA by RT-PCR in patients with Toxoplasma gondii infection relapses 189
Recovery of Enterococcus gallinarum in patients with infected cardiac pacemaker pockets. 188
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 186
Approccio multidisciplinare per il trattamento delle osteomieliti croniche e delle infezioni di dispositivi ortopedici. Risultati Preliminari 185
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection 185
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 185
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV 183
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 182
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study Disease epidemiology - Infectious 181
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 177
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality 175
Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART 175
Atazanavir/rit(atz/r),unboosted atazanavir (atz) or darunavir/rit(drv/r):metabolic safety and liver fibrosis in hiv/hcv coinfected patients (master cohort) 172
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 170
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 170
Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation 169
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 168
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 167
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 167
Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings 167
RISPOSTA VIROLOGICA SOSTENUTA DOPO TRATTAMENTO BREVE CON DI PEGINTERFERON ALFA-2A E RIBAVIRINA IN CORSO DI EPATITE CRONICA DA HCV 166
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 166
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 166
Implicazioni diagnostiche e terapeutiche in un paziente con Infezione da Parvovirus B-19 e sarcoidosi 165
Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome 165
Multidrug Resistant Bacterial Co-Infections in Critically Ill Patients with COVID-19: A Review after Three Years of Pandemic 164
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 164
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 164
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 162
ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI 162
EVALUATION OF THE SWITCH TO A DUAL ART REGIMEN WITH LAMIVUDINE PLUS DOLUTEGRAVIR OR PROTEASE INHIBITORS IN HIV-INFECTED VIROLOGICALLY SUPPRESSED PATIENTS. A REAL LIFE EXPERIENCE 159
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) 158
Broncopolmonite con empieva pleurico da Streptococcus pluranimalium in paziente tossicodipendente: considerazioni clinico-epidemiologiche. 156
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 156
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 153
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 153
Antiretroviral Therapy Partially Restores Phenotypic and Metabolic Immunosenescence Features of T Cells in Hiv Infected Individuals 152
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 152
Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort 152
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 151
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 151
Three-years follow up of raltegravir and/or maraviroc-based regimens in patients experienced to PI, NRTI, NNRTI. Update from the ISS-NIA cohort 147
Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice 146
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D Study a 144
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 144
Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice 142
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 141
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 141
Associations between immune depression and cardiovascular events in HIV infection 141
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: Data from the ICONA foundation study group, years 1997-2013 141
CD4+ T- cell count and CD4/CD8 ratio trend after HCV eradication in HCV/HIV-coinfected subjects treated with DAAs: an observational retrospective study over a 4 year period. 141
Limited occurence of new grade 3-4 toxicity events with salvage regimens based on raltegravir and /or maraviroc: 96 weeks data from the ISS NIA cohort study 140
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 138
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 137
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 137
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 137
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 136
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 136
Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens 136
Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectivness And Impact on Liver Fibrosis (MASTER Cohort) 135
Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network 134
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 134
Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy 134
PITER-HCV cohort study as part of the Italian platform for the study of viral hepatitis therapies 134
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 132
PROPORTION OF PLWH NOT VACCINATED FOR COVID-19 IN ITALY AND PREDICTORS 132
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 131
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 130
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 127
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 127
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 126
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 126
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 126
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 124
Efficacy and safety of two agents antiretroviral regimens: our experience in "real life" 124
Visits to Sexually Transmitted Infection Clinics in Italy from January 2016 to November 2021: A Multicenter, Retrospective Study 123
Endocrinological aspects of hypophosphatemia in HIV infection. Pilot study on Vitamin D supplementation: an observational study 123
ANTIRETROVIRAL THERAPY RESTORES NAÏVE T CELL FREQUENCIES OC 8 AND FUNCTIONALITY IN PLWH 122
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 122
Serious liver events and liver-related deaths in HIV/HCV co-infected patients with diabetes: data from the ICONA Foundation Cohort Study. 121
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 120
Totale 16.997
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.064
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.614
Totale 125.678
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.012 0 96 23 15 57 89 56 65 38 121 53 399
2022/2023988 158 65 66 54 173 92 52 95 117 12 71 33
2023/20241.102 55 100 82 41 115 223 27 74 34 29 37 285
2024/20254.195 101 88 350 163 469 482 155 167 683 550 540 447
2025/202610.921 1.035 396 811 1.120 1.652 638 1.376 553 978 1.037 871 454
2026/2027796 309 487 0 0 0 0 0 0 0 0 0 0
Totale 23.633